BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
Dr. Shah is an experienced healthcare finance professional with over 18 years of diverse leadership experience in investment banking and venture capital, healthcare financial consulting, business development, sales and marketing, and scientific research.
Prior to his appointment as BrainStorm’s CFO, Dr. Shah served as Director of Healthcare Investment Banking at
Dr. Shah founded and served as Managing Director of
Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from
“I am very pleased to announce that
Dr. Shah stated, “Being appointed as the Chief Financial Officer at BrainStorm is an exciting, game-changing, milestone in my career. During the extensive interview process, I learned a great deal about BrainStorm’s superior science and the potential to be the first-in-class autologous stem cell therapy for various neurogenerative diseases, the passion of every employee, and most of all, I witnessed the commitment of a small but very dedicated team who are working around the clock to fulfill the unmet medical needs for patients with devastating and heart-breaking neurodegenerative diseases. I look forward to working with Chaim and Ralph and others to bring the BrainStorm story to
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Source: BrainStorm Cell Therapeutics Inc.